Gyros Protein Technologies Upgrades Services
陀螺仪蛋白质技术AB公司是自动化纳升级免疫分析和多肽合成仪和试剂的供应商，牛津生物医学公司是一个基因和细胞治疗小组，已经投资了两套Gyrolab xPlore系统。这是Gyrolab技术首次应用于基因和细胞治疗领域。
基因和细胞疗法有可能改变医学，为广泛的疾病提供长期和潜在治愈的治疗选择。最近，几个非常有前途的细胞和基因疗法已经启动，包括GSK的Strimvelis和Novartis的Kymriah。牛津生物医药的LentiVector平台已被用于在肿瘤学，眼科和中枢神经系统疾病领域创建一系列基因和细胞治疗产品候选产品。该公司与Novartis，Bioverativ，Orchard Therapeutics和Immune Design有着强大的合作关系，并已授权Sanofi和GSK获得专利许可。
相对于单克隆抗体疗法的管道，基因和细胞治疗方案处于发展的较早阶段，在发现或临床前阶段超过75％。据该公司介绍，Gyrolab xPlore能够在生物治疗产品开发的每个阶段更加快速地开发免疫测定并提高数据质量，同时减少手工操作时间，可靠且精确地进行。
陀螺仪蛋白质技术公司还将与牛津生物医药公司合作，协助开发公司的关键分析方法。
Gyros Protein Technologies首席执行官Dan Calvo表示：“全球大多数领先的生物制药公司和CRO公司现在使用Gyrolab技术进行发现，临床前和临床开发以及单克隆抗体疗法的生物过程。“我们很高兴现在已经扩展到基因和细胞治疗这个令人兴奋的领域。我们期待着支持牛津生物医药进一步发挥其LentiVector平台的影响力。”
牛津生物医药公司首席执行官John Dawson说：“牛津生物医药公司被公认为慢病毒载体开发和生产领域的全球领先企业，其目标是开发和商业化突破性的基因和细胞药物，使用行业领先的技术，如Gyrolab xPlore，对于实现这些目标至关重要。“
Looking for chemical products? Let suppliers reach out to you!
You May Interested In
2026-07-03
-
Life Sciences Industry Overview
The coverage spans the global life sciences industry across pharmaceuticals and food & nutrition, tracking the shift from lowest-cost sourcing to supply continuity, quality, and risk management, along with product trends and the growing edge of differentiated, globally capable players.Published in: June.2026
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
Fuhrmann Hanlin Reports Strong Performance in the First Three Quarters of 2023
-
Innovating Protein Enrichment: Balancing Taste, Texture, and Nutrition in Yoghurt
-
EIT Food Advocates Protein Diversification for a Sustainable Food Industry
-
Vegan Diet Awareness Drives Meat Substitutes Market to US$67.9 Billion by 2033 | Future Market Insights, Inc.
-
Biuret Test for Protein- Test to Determine the Presence of Protein
-
Xinjiang Zhongtai Chemical was included in the 'entity list' by the United States!
-
The importance of amino acids and the cost performance of livestock and poultry feed
-
Step on the gas pedal and activate the immune checkpoint molecule 4-1BB.
-
Chinese pharmaceutical companies enter overseas to record with up to $5 billion in licensing fees!
-
The world's first! FDA approves new drug for type 1 diabetes
Recommend Reading
-
Mounjaro Usage Doubles in June Sales Surge by 18 in India
-
Alipay, Baidu, and iFlytek Win Big—As the Government Spends $1.1 Billion on AI Healthcare, Is This a Lifeline or a Feeding Frenzy for Tech Giants?
-
NHU and Sinopec Advance Liquid Methionine Project
-
After Semaglutide Patent Expiry in India, the Price System Has Been Restructured as More Than 40 Drugmakers Enter the Competition
-
FDA Clears Sanofi’s Wayrilz (rilzabrutinib) for Adult ITP; U.S. Launch in September
-
Ten Ministries Jointly Issue Notice as Five Chemicals Are Officially Added to the Hazardous Chemicals Catalogue
-
Bearish Factors Dominate, Adipic Acid Prices Decline
-
Lubei Chemical Expects First-Quarter Net Profit to Rise 57.29% as Cost Control Delivers Clear Results
-
Evonik Supervisory Board Approves Executive Changes, Extends Kullmann’s Term to 2030
-
Iran Fully Halts Petrochemical Exports as the Middle East Supply System Faces Restructuring